Manage Tickers Link Financial Account

Has my stock been accused of fraud?Join over 160k users who know.

Ticker	Price	Change($)	Change(%)	Shares	Volume	Prev Close	Open	Gain($)	Gain(%)

Ticker	Status	Jurisdiction	Filing Date	CP Start	CP End	CP Loss	Deadline

Ticker	Case Name	Status	CP Start	CP End	Deadline	Settlement Amt

Ticker	Name	Date	Analyst Firm	Up/Down	Target ($)	Rating Change	Rating Current

Analyst Rating Guide

News

Back

OncoCyte Q4 EPS $(2.18) Misses $(1.14) Estimate, Sales $314.00K Miss $316.67K Estimate

Author: Benzinga Newsdesk | April 12, 2024 06:07am

OncoCyte (NASDAQ:OCX) reported quarterly losses of $(2.18) per share which missed the analyst consensus estimate of $(1.14) by 91.23 percent. The company reported quarterly sales of $314.00 thousand which missed the analyst consensus estimate of $320.00 thousand by 1.88 percent.

Posted In: OCX